KLK3 and prostate cancer: The risk reduction for prostate cancer was also confined to those men who had baseline PSA levels ≤ 4.0 ng/mL (RR: 0.35, 95% CI: 0.13–0.87), although no significant interaction was observed between treatment and baseline PSA [57].